Drug-induced Fatty Liver Disease:Pathogenesis and Treatment  

作　　者：Tea Omanovic Kolaric Vjera Nincevic Lucija Kuna Kristina Duspara Kristina Bojanic Sonja Vukadin Nikola Raguz-Lucic George Y Wu Martina Smolic 

机构地区：[1]University of Osijek,Faculty of Medicine,Osijek,Croatia [2]University of Osijek,Faculty of Dental Medicine and Health,Osijek,Croatia [3]Health Center Osijek,Osijek,Croatia [4]Department of Medicine,Division of Gastroenterology-Hepatology,University of Connecticut Health Center,Farmington,CT,USA

出　　处：《Journal of Clinical and Translational Hepatology》2021年第5期731-737,共7页临床与转化肝病杂志（英文版）

基　　金：The study was funded by a grant from Croatian Ministry of Science and Education(dedicated to multi-year institutional funding of scientific activity at the J.J.Strossmayer University of Osijek,Osijek,Croatia,under grant number:IP10-MEFOS-2019 to MS);Support from the Herman Lopata Chair in Hepatitis Research is also gratefully acknowledged(to GYW).

摘　　要：Metabolic dysfunction-associated fatty liver disease(commonly known as MAFLD)impacts global health in epidemic proportions,and the resulting morbidity,mortality and economic burden is enormous.While much attention has been given to metabolic syndrome and obesity as offending factors,a growing incidence of polypharmacy,especially in the elderly,has greatly increased the risk of drug-induced liver injury(DILI)in general,and drug-induced fatty liver disease(DIFLD)in particular.This review focuses on the contribution of DIFLD to DILI in terms of epidemiology,pathophysiology,the most common drugs associated with DIFLD,and treatment strategies.

关 键 词：Metabolic dysfunction-associated fatty liver disease Drug-induced liver injury Reactive oxygen species Free fatty acids PHARMACOGENETICS 

分 类 号：R57[医药卫生—消化系统]